MdxHealth (TM) : MDxHealth (TM) : Annual and Extraordinary General
IRVINE, CA, and LIEGE, BELGIUM, 31 May, 2013 -MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostic company that develops and commercializes
epigenetic tests to support cancer treatment, held its Annual and
Extraordinary General Meeting of shareholders in Zaventem today. The
shareholders approved all agenda items of the Annual General Meeting,
including the financial statements for the financial year ended 31 December
The quorum requirement for deliberation and voting on the agenda items of the
Extraordinary General Meeting was not met. A second Extraordinary General
Meeting will be held on Thursday 27 June 2013 at 10:00 AM at the Airport
Meeting Center, Brussels Airport, Box 75, 1930 Zaventem, Belgium, or at such
place as will be indicated at that place at that time.
MDxHealth is a molecular diagnostics company that develops and commercializes
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first commercial product, ConfirmMDx^TM for
Prostate Cancer, has been shown to help distinguish patients who have a
true-negative biopsy from those who may have undetected cancer. MDxHealth
helps to address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary platform
and a strong epigenetic product pipeline focused on the development of
products for prostate, brain, lung and colon cancers. The company is based in
Irvine, California with a European headquarters in Liege, Belgium. For more
information visit MDxHealth's website at www.mdxhealth.com.
For more information: Mike Sinclair Seth Lewis
Dr. Jan Groen, CEO Halsin Partners The Trout Group
MDxHealth UK: +44 20 7318 2955
US: +1 949 812 6979 Cell: +44 7968 022075 US: +1 646 378 2952
BE: +32 4 364 20 70 email@example.com firstname.lastname@example.org
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of securities or
assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be
offered or sold within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an exemption
therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service
marks are the property of their respective owners.
To access the PDF version, please click here
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: MdxHealth (TM) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.